EUVIMEDEUVIMED entdecken
Übersichtsarbeit

GLP-1 Receptor Agonists May Reduce Insulin Requirements in New-Onset Type 1 Diabetes

Justin M Gregory

Endocrinology and Metabolism Clinics of North America · 2026-09 · 55 (3) · 455-466

DOI: 10.1016/j.ecl.2026.04.010 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Endocrinology and Metabolism Clinics of North America, 2026-09. Verfasst von Justin M Gregory. Beteiligte Einrichtung: Autoimmune Type 1 Diabetes, Sanofi, 100 Morris Street, Morristown, NJ 07960, USA. Electronic address: Justin.Gregory2@sanofi.com. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Glucagon-Like Peptide-1 Receptor Agonists, Insulin, Hypoglycemic Agents. Die Arbeit nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Early stage 3 type 1 diabetes is a period of rapid pathophysiologic change. Flagging beta-cell secretion is accompanied by postprandial hyperglucagonemia, impaired incretin amplification, beta-cell stress, and insulin resistance. Incretin-based therapy may align favorably with these defects by augmenting glucose-dependent insulin secretion, improving postprandial hyperglucagonemia, reducing beta-cell stress and insulin resistance. Randomized trials initiating glucagon-like peptide 1 receptor agonist therapy soon after diagnosis demonstrate lower insulin requirements and better-preserved stimulated C-peptide while on treatment, but these advantages often diminish after discontinuation. Combination approaches pairing immunomodulatory therapy with incretin-based metabolic support may improve durability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Glucagon-Like Peptide-1 Receptor AgonistsInsulinHypoglycemic AgentsHumansGlucagon-Like Peptide-1 Receptor

Stichwörter der Autor:innen

C-peptide preservationEarly stage 3 type 1 diabetesGLP-1 receptor agonistsHyperglucagonemiaImmunotherapyIncretin receptor agonistsType 1 diabetes

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsInsulinHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor

Autor:innen und Institutionen

  • Autoimmune Type 1 Diabetes, Sanofi, 100 Morris Street, Morristown, NJ 07960, USA. Electronic address: Justin.Gregory2@sanofi.com.

Zitieren

APA

Gregory, J. M. (2026). GLP-1 Receptor Agonists May Reduce Insulin Requirements in New-Onset Type 1 Diabetes. Endocrinology and Metabolism Clinics of North America, 55(3), 455-466. https://doi.org/10.1016/j.ecl.2026.04.010

Vancouver

Gregory JM. GLP-1 Receptor Agonists May Reduce Insulin Requirements in New-Onset Type 1 Diabetes. Endocrinology and Metabolism Clinics of North America. 2026;55(3):455-466. doi:10.1016/j.ecl.2026.04.010

BibTeX
@article{Gregory2026,
  author = {Gregory, Justin M},
  title = {GLP-1 Receptor Agonists May Reduce Insulin Requirements in New-Onset Type 1 Diabetes},
  journal = {Endocrinology and Metabolism Clinics of North America},
  year = {2026},
  volume = {55},
  number = {3},
  pages = {455--466},
  doi = {10.1016/j.ecl.2026.04.010}
}
Kostenlos starten →